Technology platform

Pix 30


Affinicon produces combined drugs by linking drugs with known pharmacological effect to a receptor binding partner protein,  that carries the drug to the desired site of action - the macrophage.

The proprietary use of the specific CD163 macrophage receptor for targeting is unique and superior to other macrophage targets.


- The Affinicon CD163-targeting platform is applicable for a number of drugs

- The technology can be used for increasing efficacy of existing drugs - or candidates terminated due to adverse effects or bioavailability

- Fewer side effects, increased safety, more indications

- Shortened discovery time and possibilities for faster approval by regulatory authorities


Affinicon ApS Science Park Aarhus, Aabogade 15, 8200 Aarhus N